Is Etodolac a Controlled Substance?
No, etodolac is not a controlled substance. It is a nonsteroidal anti-inflammatory drug (NSAID) available by prescription in the United States and does not have any scheduling under the Controlled Substances Act 1.
Classification and Availability
Etodolac is classified as a prescription NSAID, specifically a pyranocarboxylic acid derivative with selective COX-2 inhibitory properties 2, 3. It requires a prescription for dispensing but has no restrictions related to controlled substance regulations. This means:
- No DEA registration required for prescribing
- No special prescription forms needed (unlike Schedule II-V medications)
- No quantity or refill limitations beyond standard prescribing practices
- Available in generic formulations at standard pharmacy pricing 4
Clinical Context
Etodolac is FDA-approved for the management of osteoarthritis, rheumatoid arthritis, and acute pain 1. The drug is available in immediate-release formulations (200-400 mg doses) and extended-release formulations (400-1000 mg daily dosing) 4, 1.
The medication demonstrates efficacy comparable to other commonly prescribed NSAIDs like ibuprofen and naproxen, with evidence suggesting superior gastrointestinal tolerability compared to some nonselective NSAIDs 5, 2. Among NSAIDs, data indicate that etodolac may have superior GI safety profiles alongside ibuprofen and nabumetone 5.
Important Prescribing Considerations
While not controlled, etodolac carries significant risks that require careful patient selection and monitoring:
- Cardiovascular risks including myocardial infarction and stroke
- Gastrointestinal bleeding with risk increasing with age (1 in 110 for adults over 75 years) 4
- Renal impairment and potential for acute kidney injury 1
- Contraindicated in pregnancy at ≥30 weeks gestation due to premature ductus arteriosus closure 1